Safety And Seroconversion Of Immunotherapies Against SARS-CoV-2 Infection: A Systematic Review And Meta-Analysis Of Clinical Trials Part 1

Abstract: 

Clinical trials evaluating the safety and antibody response of strategies to manipulate prophylactic and therapeutic immunity have been launched. We aim to evaluate strategies for augmentation of host immunity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) infection. 

Therapeutic immune strategy uses the human immune system to fight diseases and has broad application prospects. In recent years, with an in-depth understanding of the immune system, people have gradually discovered a close relationship between therapeutic immune strategies and memory.

Research shows that therapeutic immune strategies can enhance the body's resistance by improving the stability and coping capabilities of the immune system. This immune improvement also plays a role in improving memory. The reason is that immune cells release many growth factors and neurotrophic factors when responding to diseases. These substances have a positive impact on the growth and development of nerve cells and are conducive to promoting memory function.

In addition, therapeutic immune strategies can also regulate the neuroendocrine system and relieve tension and stress within the body. This regulation can promote the normal metabolism of brain cells, protect the health of nerve cells, and enhance the stability and persistence of memory.

Taken together, the impact of therapeutic immunization strategies on memory is positive. It can promote the growth and development of nerve cells and enhance memory function; it can also relieve tension and stress and enhance the stability and persistence of memory. Therefore, we should actively promote therapeutic immunity strategies to improve people's immune status, increase the body's resistance, and thereby promote memory. It can be seen that we need to improve memory, and Cistanche deserticola can significantly improve memory because Cistanche deserticola is a traditional Chinese medicinal material that has many unique effects, one of which is to improve memory. The efficacy of Cistanche deserticola comes from the multiple active ingredients it contains, including tannic acid, polysaccharides, flavonoid glycosides, etc. These ingredients can promote brain health through a variety of pathways.

Click know 10 ways to improve memory

We searched clinical trials registered at the National Institutes of Health by 25 May 2021 and conducted analyses on inoculated populations, involved immunological processes, source of injected components, and trial phases. 

We then searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials for their corresponding reports published by 25 May 2021. A bivariate, random-effects meta-analysis was used to derive the pooled estimate of seroconversion and adverse events (AEs). A total of 929,359 participants were enrolled in 389 identified trials. 

The working mechanisms included heterologous immunity, active immunity, passive immunity, and immunotherapy, with 62.4% of the trials on vaccines. A total of 9072 healthy adults from 27 publications for 22 clinical trials on active immunity implementing vaccination were included for meta-analyses. 

The pooled odds ratios (ORs) of seroconversion were 13.94, 84.86, 106.03, and 451.04 (all p < 0.01) for vaccines based on protein, RNA, viral vector, and inactivated virus, compared with that of respective placebo/control treatment or pre-vaccination sera. 

The pooled ORs for safety, as defined by the inverse of systemic adverse events (AEs) were 0.53 (95% CI = 0.27–1.05; p = 0.07), 0.35 (95% CI = 0.16–0.75; p = 0.007), 0.32 (95% CI = 0.19–0.55; p < 0.0001), and 1.00 (95% CI = 0.73–1.36; p = 0.98) for vaccines based on protein, RNA, viral vector, and inactivated virus, compared with that of placebo/control treatment. 

A paradigm shift from all four immune-augmentative interventions to active immunity implementing vaccination was observed through clinical trials. The efficacy of immune responses to neutralize SARS-CoV-2 for these vaccines was promising, although systemic AEs were still evident for RNA-based and viral vector-based vaccines.

Keywords: coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); heterologous immunity; active immunity; passive immunity.

1. Introduction

Coronavirus disease 2019 (COVID-19), caused by the corresponding pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly threatened global health and economic systems [1,2]. 

Belonging to the Coronaviridae family, SARS-CoV-2 contains a positive single-strand RNA genome of 29.8 to 29.9 kb, which encodes two replicase/transcriptase ORF1ab and six accessory proteins, as well as four structural proteins, including nucleocapsid (N), envelop (E), membrane (M) and spike (S) proteins, with the last being the protein crucial to infecting target cells via binding to the angiotensinconverting enzyme II (ACE2) [3]. 

As a highly contagious virus, transmission sources of SARS-CoV-2 include discharge or direct contact with droplets and fomites that contain virus particles through the mouth, nose, or eyes. 

As of 25 May 2021, according to the Johns Hopkins Centers for Civic Impact [4], there were 170,354,142 confirmed cases and 3,541,800 deaths, with a mortality rate of 2.08%. 

Among all registered regions, the United States had the most cases of COVID-19, with 33,200,765 confirmed cases and 593,419 deaths. To date, rising numbers of clinical trials on the safety and antibody response of strategies to manipulate prophylactic and therapeutic immunity have been launched.

Host immunity is one of the most effective defense mechanisms against severely infectious diseases through comprehensive regulations in the immune system. If COVID-19 is to be effectively controlled, the most pivotal measure would be the development of effective immunity via vaccination or direct transfer of immunity for prophylactic or therapeutic purposes. 

Generally, three pathways of immunity induction are classified: vaccination to induce heterologous immunity or active immunity, transfer of active humoral immunity, which is also called passive immunity, and direct manipulation of immunity known as immunotherapy [5]. 

Among them, heterologous immunity refers to the induction of cross-protection by training innate immunity via vaccination of irrelevant pathogens [6]. On the other hand, active immunity triggers adaptive immune responses that involve both cellular and humoral responses with vaccine-induced immunological memory, while passive immunity utilizes antibodies against pathogen spreading and infection [7]. 

Immunotherapy is originally designed for the treatment of cancer by enhancement of anti-tumor immune activity via transfer of immune activator/cells or blockage of suppressor signals, such as programmed cell death protein-1 (PD-1)/PD-L1 pathway [8].

The holy grail that numerous clinicians and scientists strive for during the COVID-19 crisis has been the successful vaccine or direct transfer of protective immunity. The purpose of this article is therefore to introduce and discuss these ongoing clinical trials registered at the National Institutes of Health (NIH) (ClinicalTrials.gov) for a systemic review and perform a meta-analysis on safety and antibody response for published results from current trials.

2. Results

2.1. Systematic Review of Clinical Trials

As of 25 May 2021, we appraised 389 registered clinical trials for COVID-19 based on non-pharmaceutical interventions (NPIS) for augmenting immunity, specifically vaccination or immunotherapy. 

A total of 929,359 healthy adult populations susceptible to SARS-CoV-2 infection or patients with COVID-19 were enrolled in those clinical trials. Moreover, increasing numbers of registered trials aimed at inducing active immunity were observed in more current months (Figure 1). 

According to their working mechanisms, the 389 clinical trials may be classified into vaccination for induction of heterologous or active immunity, immunoglobulin transfer for providing passive immunity, and immunotherapy (Table 1, trial numbers; Table 2, participant numbers).

2.1.1. Cross-Protective Vaccines Realizing Heterologous Immunity

Although they do not directly target SARS-CoV-2, the off-label use of Mycobacterium (phase 3: n = 19, participants = 29,202; phase 4: n = 6, participants = 10,864), measles mumps and rubella (MMR, phase 3: n = 2, participants = 260), poliovirus (phase 3: n = 1, participants = 3600; phase 4: n = 2, participants = 3425), and Zoster (phase 1: n = 1, participants = 250) vaccines have been rapidly authorized for clinical trials due to their well-established safety and potential to induce heterologous immunity. 

Among 26 trials using Mycobacterium vaccines, 20 of them used BCG, including 19 for prevention and one for therapy (trial number NCT04369794), in which humoral response against SARS-CoV-2 for the elimination of symptoms in patients with COVID-19. 

To determine whether BCG vaccination may prevent COVID-19 progression, we analyzed epidemiological data of reported COVID-19 cases by 12 September 2020, which was commonly used as a substitute when vaccination was not popularized. 

The retrieved data were from high-income countries whose claimed healthcare data on the BCG World Atlas [9] were considered reflective of the larger population (Supplementary Table S1). 

Although the incidence rate of COVID-19 was not different in countries with versus without BCG vaccination policy (Supplementary Figure S1A), the average mortality rate was significantly lower in countries implementing BCG vaccination policy (2.17%, ranging from 0% to 5.83%) than that of countries without such policy (5.1%, ranging from 0.73% to 12.56%) (Supplementary Figure S1B), suggesting the efficacy of BCG-mediated training or heterologous immunity for fir alleviating complications of COVID-19. Our cross-sectional analyses revealed significant differences in mortality for COVID-19 among countries with and without current BCG vaccination policies, indicating the protective role of BCG immunization on the induction of heterologous immunity against SARS-CoV-2.

 During the pandemic, off-label use of vaccines such as BCG and MMR vaccines [10] have been repurposed in the hope of establishing heterologous immunity against SARS-CoV-2 and have been provided to individuals with high-risk occupations for COVID-19, including healthcare providers.

For more information:1950477648nn@gmail.com